PMID- 22519390
OWN - NLM
STAT- MEDLINE
DCOM- 20121105
LR  - 20191210
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 28
IP  - 6
DP  - 2012 Jun
TI  - Metabolic outcomes of elderly patient populations initiating exenatide BID versus 
      insulin glargine in an ambulatory care setting.
PG  - 991-7
LID - 10.1185/03007995.2012.686901 [doi]
AB  - AIMS: The safety and efficacy of exenatide BID (exenatide) and insulin glargine 
      (glargine) have been studied in clinical trials with few elderly patients. This 
      study examined the clinical effectiveness of exenatide compared to glargine in 
      patients 65 years and older with type 2 diabetes mellitus (T2DM). METHODS: A 
      retrospective analysis was conducted using the General Electric electronic 
      medical record database. Patients aged 65 years and older with T2DM who initiated 
      exenatide or glargine were identified between November 1, 2006 and April 30, 2009 
      with 12 months of pre- and post-index continuous eligibility. Propensity-score 
      matching (1:1) was used to balance baseline differences between the cohorts. The 
      effectiveness endpoints were changes in A1C (primary endpoint), weight, body mass 
      index (BMI), and blood pressure (BP). Matched cohorts were compared using paired 
      t tests and nonparametric tests as appropriate. RESULTS: The matched exenatide 
      and glargine patients (n = 804 each) were comparable in their baseline 
      characteristics, including age (70 vs. 71 years), and male sex (44.9% vs. 45.2%). 
      In the 12-month follow-up, exenatide patients experienced significantly greater 
      mean reductions in A1C (-0.5 vs. -0.2%), weight (-2.8 vs. -0.2 kg), BMI (-1.0 vs. 
      -0.1 kg/m(2)), and systolic BP (-2.2 vs. 1.0 mmHg) (all: P < 0.05). More 
      exenatide-treated patients reached the A1C goal of <7% (53.9% vs. 43.0%, 
      P < 0.01). Diastolic BP was similar between the cohorts. LIMITATIONS: Unmeasured 
      confounding bias may still exist and thus findings should be interpreted as 
      associations instead of causations. Due to incomplete data, adverse events and 
      medication use were not examined. CONCLUSION: Exenatide was associated with 
      significant improvement in A1C, weight, BMI and BP compared to glargine for 
      management of T2DM in an elderly patient population treated in ambulatory care 
      settings.
FAU - Pawaskar, Manjiri
AU  - Pawaskar M
AD  - Eli Lilly and Company, Indianapolis, IN, USA.
FAU - Li, Qian
AU  - Li Q
FAU - Reynolds, Matthew W
AU  - Reynolds MW
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120509
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin, Long-Acting)
RN  - 0 (Peptides)
RN  - 0 (Venoms)
RN  - 2ZM8CX04RZ (Insulin Glargine)
RN  - 9P1872D4OL (Exenatide)
SB  - IM
MH  - *Aged
MH  - Ambulatory Care/methods
MH  - *Ambulatory Care Facilities
MH  - Cohort Studies
MH  - Diabetes Mellitus, Type 2/*drug therapy/*metabolism
MH  - Exenatide
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/therapeutic use
MH  - Insulin Glargine
MH  - Insulin, Long-Acting/*therapeutic use
MH  - Male
MH  - Peptides/administration & dosage/*therapeutic use
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Venoms/administration & dosage/*therapeutic use
EDAT- 2012/04/24 06:00
MHDA- 2012/11/06 06:00
CRDT- 2012/04/24 06:00
PHST- 2012/04/24 06:00 [entrez]
PHST- 2012/04/24 06:00 [pubmed]
PHST- 2012/11/06 06:00 [medline]
AID - 10.1185/03007995.2012.686901 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2012 Jun;28(6):991-7. doi: 10.1185/03007995.2012.686901. Epub 
      2012 May 9.